Maryland Archives

Prostate Cancer Initial Staging and Evaluation of Recurrent Disease with PSMA-Targeted PET

Posted by Steven P. Rowe, MD, PhD | Feb 2020

Steven Rowe, MD, PhD, gives an overview of current data on prostate-specific membrane antigen (PSMA)-targeted PET imaging for initial staging of prostate cancer (PCa) and evaluation of recurrent disease. He emphasizes PSMA’s limited sensitivity for initial diagnosis and high sensitivity for recurrent disease, while also noting potential strengths and weaknesses of PSMA that are independent of sensitivity.

Penile Allotransplantation: An Advance in Genitourinary Reconstruction

Posted by Arthur L. Burnett II, MD, MBA, FACS | Sep 2019

Arthur L. Burnett II, MD, MBA, presents penile allotransplantation as an emerging alternative to autogenous reconstruction. He discusses the benefits for military trauma patients in particular, and the importance of considering potential complications as well as improved quality of life.

New Frontiers in Cavernous Nerve Restorative Therapy to Preserve Erectile Function after Radical Prostatectomy

Posted by Arthur L. Burnett II, MD, MBA, FACS | Aug 2019

Arthur L. Burnett II, MD, MBA, FACS, presents the rationale for invoking therapeutic strategies for enhancing erectile function recovery following radical prostatectomy. He assesses possible therapeutic strategies that target the cavernous nerve in order to restoring erectile function and identifies the requirements and future possibilities for penile rehabilitation success.

Recent Findings on Upper Tract Urothelial Carcinoma Presented at the AUA’s 2019 Annual Meeting

Posted by Phillip M. Pierorazio, MD | Aug 2019

Phillip M. Pierorazio, MD, reviews data from one presentation and two moderated posters at the American Urological Association’s 2019 Annual Meeting related to upper tract urothelial cancer (UTUC). He discusses the promising efficacy of UGN-101 to treat low-grade UTUC as shown in the OLYMPUS trial, details data that supports the use of intravesical therapy to prevent recurrence of bladder cancer in patients with upper-tract disease, and argues that concordant or discordant pathology should have little bearing on treatment options for patients suspected of having high-grade UTUC.

Fexapotide for BPH

Posted by Ronald F. Tutrone, Jr., MD, FACS, CPI | May 2018

Ronald F. Tutrone, Jr., MD, FACS, summarizes two Phase III clinical trials testing the safety and efficacy of fexapotide, a novel treatment for benign prostatic hyperplasia (BPH).